ArticleJournal of orthopaedic case reports2026
Efficacy and Safety of Fixed Dose Combination of Inosine Monophosphate, Agmatine Sulphate, and L-Carnosine (CGXNW) as Add-on Therapy for the Management of Spinal Cord Injury - A Randomized Controlled Clinical Trial.
Article in Journal of orthopaedic case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: A prospective, single-center, randomized, controlled, parallel-arm clinical trial involving 120 patients with subacute spinal cord injury (SCI). Participants were randomized (1:1) to receive standard care alone or standard care plus CGXNW for 6 months. Neurological recovery, functional independence, and safety were systematically evaluated. Purpose: To determine whether CGXNW, a multi-target neurorestorative formulation, can improve motor and sensory recovery, functional independence, and quality of life (QOL) when used as an adjunct to conventional therapy in subacute SCI. Overview of Literature: SCI results in long-term neurological deficits with limited restorative pharmacotherapies. Mechanistic targets include excitotoxicity, oxidative stress, and impaired neuroplasticity. Inosine, agmatine, and L-carnosine individually demonstrate neuroprotective and neuroregenerative potential. Materials and Methods: Eligible subacute SCI patients were allocated into two arms receiving either routine institutional management or adjunct CGXNW for 180 days. Neurological status (international standards for neurological classification of spinal cord injury motor/sensory, ASIA impairment scale), independence (spinal cord independence measure III [SCIM-III] domains), quality-of-life scores, and adverse events were recorded at pre-defined intervals. Results: The CGXNW group demonstrated significantly greater improvements in motor scores, SCIM-III total scores, and QOL at Day 180 compared to the standard treatment group. Sensory scores showed no significant differences. Only three minor, short-lasting adverse events were seen in the CGXNW group, with no serious events reported. Conclusion: CGXNW as an adjunct to standard care significantly enhances motor function, functional independence, and QOL in subacute SCI, with a favorable safety profile. Larger, multicenter trials are needed to confirm these findings and assess long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.